A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Zenas BioPharma, Inc. ZBIO
Promising (early) broader-coverage candidate · Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The co
On FrontierLab's discovery record since 2026-07-15 (11 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-10-02), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | -0.09 |
| Rule of 40 | -47650.6 |
| Net margin | -47557.3% |
| Cash runway (months) | 34.2 |
| PEG | — |
| Price / sales | 1763.9 |
Quality checklist
- ✓ Capital efficiency
- ~ Share dilution — 50.8%
Fundamentals — snapshot as of 2026-10-02
| Stage | Early |
|---|---|
| Share issuance (YoY) | 50.8% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-9.62 |
| Burn multiple | — |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.92 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-13 |
Momentum context — a snapshot from 2026-10-02, not current
| Price at surface | $27.94 (as of 2026-10-02) |
|---|---|
| 52-week range | $13.5 – $44.6 |
| % off 52-wk high | -37.4% |
| RSI (14) | 40 |
| Relative volume | 1.3× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-10-02 (end-of-day). How grades are computed →